Tafamidis Active Not Recruiting Phase 3 Trials for Transthyretin (TTR) Amyloid Cardiomyopathy Treatment

Back to Tafamidis
IndicationsStatusPurposePhase
Active Not RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02791230Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy